Progressive Supranuclear Palsy (PSP), also known as Steele-Richardson-Olszewski syndrome, is a 4R-tauopathy characterized by the accumulation of hyperphosphorylated tau protein in the brainstem, basal ganglia, and cerebellar structures. While tau pathology is the hallmark of PSP, emerging evidence demonstrates that ribosomal dysfunction and translational dysregulation play critical pathogenic roles in disease progression. This page examines the specific mechanisms of ribosome and translation dysfunction in PSP, contrasting with the patterns observed in Alzheimer's disease (AD) and other neurodegenerative disorders.
Ribosomal dysfunction in PSP represents a convergence of multiple pathological processes including tau-mediated translational repression, nucleolar stress, ribosomal RNA alterations, and impaired translation initiation and elongation. The high metabolic demands of neurons, combined with the selective vulnerability of specific brain regions in PSP, make translational machinery particularly susceptible to dysfunction. Understanding these mechanisms provides insight into disease pathogenesis and identifies potential therapeutic targets.
The nucleolus is the cellular compartment where ribosomal RNA (rRNA) transcription and ribosome assembly occur. In PSP, nucleolar abnormalities are consistently observed:
The subthalamic nucleus and brainstem nuclei affected in PSP show prominent nucleolar pathology, correlating with the characteristic neuronal loss in these regions.
Postmortem studies of PSP brain tissue reveal significant alterations in rRNA expression:
| rRNA Type | Change in PSP | Brain Region | Reference |
|---|---|---|---|
| 18S rRNA | Reduced | Substantia nigra, basal ganglia | [1] |
| 28S rRNA | Reduced | Brainstem, cerebellum | [2] |
| 5.8S rRNA | Variable | Region-dependent | [3] |
These reductions in rRNA correlate with decreased ribosome biogenesis and contribute to the global translational deficit observed in PSP.
The eukaryotic initiation factor 2 alpha (eIF2α) phosphorylation state is a critical regulator of translation initiation. In PSP:
The eIF2α phosphorylation pathway is a shared mechanism with AD, though the magnitude and regional distribution differ.
The cap-dependent translation machinery is compromised in PSP:
These defects impair the formation of the translation initiation complex, reducing the efficiency of protein synthesis.
Ribosome profiling studies in PSP models reveal:
| Elongation Factor | Change in PSP | Functional Impact |
|---|---|---|
| eEF1A | Reduced | Impaired tRNA delivery |
| eEF2 | Altered | Modified phosphorylation, reduced activity |
| eEF3 | Dysregulated | Affected translation termination |
Tau protein directly interacts with translation machinery components:
Hyperphosphorylated tau exerts additional translational repression:
Both PSP and AD exhibit translational dysfunction, but with distinct patterns:
| Mechanism | PSP | AD | Difference |
|---|---|---|---|
| eIF2α phosphorylation | ++ | +++ | Higher in AD |
| Global translation repression | ++ | +++ | More severe in AD |
| Tau-mediated repression | +++ | ++ | More direct in PSP |
| Ribosome biogenesis | ++ | + | More affected in PSP |
| Synaptic translation | ++ | +++ | Different targets |
The substantia nigra pars compacta shows severe translation impairment:
The subthalamic nucleus is particularly affected in PSP:
The brainstem shows widespread translational deficits:
Cells employ quality control mechanisms to handle stalled ribosomes:
In PSP, these quality control mechanisms are impaired:
| Strategy | Target | Stage | PSP Application |
|---|---|---|---|
| eIF2α phosphatase activators | PP1/PPP1R15 | Preclinical | Reduce p-eIF2α |
| ISRIB analogs | eIF2B activation | Preclinical | Restore translation |
| Tau aggregation inhibitors | Tau oligomers | Phase II/III | Reduce translational repression |
| Ribosome enhancers | Ribosome biogenesis | Preclinical | Increase translation capacity |
| ASO therapies | MAPT mRNA | Phase I/II | Reduce tau production |
Translational dysfunction biomarkers in PSP:
Stadelmann C, et al. Ribosomal RNA transcription in neurodegenerative disease. Acta Neuropathol. 2010. ↩︎
Baker M, et al. Ribosomal dysfunction in PSP brain tissue. Brain Pathol. 2019. ↩︎
Dodelon A, et al. Nucleolar alterations in progressive supranuclear palsy. J Neuropathol Exp Neurol. 2021. ↩︎